drugset
drugset / Trial / NCT05349643

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

NCT05349643 ↗

Phase 2 Completed 20 enrolled AmMax Bio, Inc.
NaSingle-groupOpen-labelTreatment

Summary

AMB-051-07 is an open-label, adaptive, dose-ranging study with long-term extension in adults with tenosynovial giant cell tumor

Timeline

Start
2023-01-26
Primary completion
2024-06-03
Completion
2024-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject AMB-05X Monoclonal antibody — Other

Indications

tenosynovial giant cell tumor